Updated picture of SARS-CoV-2 variants and mutations
暂无分享,去创建一个
[1] A. M. Kilpatrick,et al. Estimates of reduced vaccine effectiveness against hospitalization, infection, transmission and symptomatic disease of a new SARS-CoV-2 variant, Omicron (B.1.1.529), using neutralizing antibody titers , 2021, medRxiv.
[2] J. Nie,et al. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron , 2021, Emerging microbes & infections.
[3] A. Sigal,et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection , 2021, medRxiv.
[4] S. Hoehl,et al. Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies , 2021, medRxiv.
[5] M. Chawla-Sarkar,et al. S glycoprotein diversity of the Omicron Variant , 2021, medRxiv.
[6] J. Doudna,et al. Rapid assessment of SARS-CoV-2–evolved variants using virus-like particles , 2021, Science.
[7] Philip L. Tzou,et al. The biological and clinical significance of emerging SARS-CoV-2 variants , 2021, Nature Reviews Genetics.
[8] G. Lippi,et al. Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role? , 2021, Clinical chemistry and laboratory medicine.
[9] D. Barh,et al. Emergence of unique SARS-CoV-2 ORF10 variants and their impact on protein structure and function , 2021, International Journal of Biological Macromolecules.
[10] Rezwanuzzaman Laskar,et al. Differential mutation profile of SARS-CoV-2 proteins across deceased and asymptomatic patients , 2021, Chemico-Biological Interactions.
[11] J. Derrick,et al. Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion , 2021, International journal of molecular sciences.
[12] J. Dushoff,et al. The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic , 2021, Current Biology.
[13] G. Lippi,et al. Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How? , 2021, Diagnostics.
[14] J. Dushoff,et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa , 2021 .
[15] OUP accepted manuscript , 2021, Virus Evolution.
[16] Lanjuan Li,et al. Patient-derived SARS-CoV-2 mutations impact viral replication dynamics and infectivity in vitro and with clinical implications in vivo , 2020, Cell discovery.
[17] M. Kearney,et al. Low genetic diversity may be an Achilles heel of SARS-CoV-2 , 2020, Proceedings of the National Academy of Sciences.
[18] E. Callaway. The coronavirus is mutating — does it matter? , 2020, Nature.
[19] Y. Furuichi,et al. RNA‐dependent RNA polymerase, RdRP, a promising therapeutic target for cancer and potentially COVID‐19 , 2020, Cancer science.
[20] MingKun Li,et al. Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] G. Lippi,et al. The novel coronavirus (2019-nCoV) outbreak: think the unthinkable and be prepared to face the challenge , 2020, Diagnosis.
[22] F. Checchi,et al. Deaths, late deaths, and role of infecting dose in Ebola virus disease in Sierra Leone: retrospective cohort study , 2016, British Medical Journal.
[23] Robert J. Taylor,et al. Global Mortality Estimates for the 2009 Influenza Pandemic from the GLaMOR Project: A Modeling Study , 2013, PLoS medicine.
[24] J. Sanford,et al. A new look at an old virus: patterns of mutation accumulation in the human H1N1 influenza virus since 1918 , 2012, Theoretical Biology and Medical Modelling.